

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6669052

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
CHARLES RIVER LABORATORIES, INC.		04/21/2021
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	JPMORGAN CHASE BANK, N.A.	
<b>Street Address:</b>	10 S. DEARBORN, 7TH FLOOR, 1-1625	
<b>City:</b>	CHICAGO	
<b>State/Country:</b>	ILLINOIS	
<b>Postal Code:</b>	60603	
<b>PROPERTY NUMBERS Total: 21</b>		
<b>Property Type</b>	<b>Number</b>	
Patent Number:	10119969	
Patent Number:	10473663	
Patent Number:	10473664	
Patent Number:	10465228	
Patent Number:	D831223	
Patent Number:	D821604	
Patent Number:	10324036	
Patent Number:	D719666	
Patent Number:	D726929	
Patent Number:	D829340	
Patent Number:	D821605	
Patent Number:	D829338	
Application Number:	16133828	
Application Number:	63148916	
Application Number:	16284495	
Application Number:	16675978	
Application Number:	17178608	
Application Number:	17193597	
Application Number:	15577153	
Application Number:	16156740	

PATENT

<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16899519

**CORRESPONDENCE DATA**

**Fax Number:**  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 202-370-4750

**Email:** ipteam@cogencyglobal.com

**Correspondent Name:** JOANNA MCCALL

**Address Line 1:** 1025 VERMONT AVE NW, SUITE 1130

**Address Line 2:** COGENCY GLOBAL INC.

**Address Line 4:** WASHINGTON, D.C. 20005

<b>ATTORNEY DOCKET NUMBER:</b>	1360022 CRL
<b>NAME OF SUBMITTER:</b>	WENNY ZHU
<b>SIGNATURE:</b>	/Wenny Zhu/
<b>DATE SIGNED:</b>	04/21/2021

**Total Attachments: 5**  
source=Patent Security Agreement CRL Inc#page2.tif  
source=Patent Security Agreement CRL Inc#page3.tif  
source=Patent Security Agreement CRL Inc#page4.tif  
source=Patent Security Agreement CRL Inc#page5.tif  
source=Patent Security Agreement CRL Inc#page6.tif

GRANT OF  
SECURITY INTEREST IN PATENT RIGHTS

THIS GRANT OF SECURITY INTEREST IN PATENT RIGHTS (“Agreement”), effective as of April 21, 2021 is made by Charles River Laboratories, Inc., a corporation formed under the laws of Delaware (the “Obligor”), in favor of JPMorgan Chase Bank, N.A., as Administrative Agent (the “Agent”) for the several banks and other financial institutions (the “Lenders”), parties to the Ninth Amended and Restated Credit Agreement, dated as of the date hereof (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Charles River Laboratories International, Inc., a Delaware corporation and parent of Obligor (“Parent Borrower”), certain Subsidiaries of the Parent Borrower, the Lenders and the Agent.

W I T N E S S E T H:

WHEREAS, pursuant to the Credit Agreement, the Lenders have severally agreed to make Loans and other extensions of credit to the Parent Borrower upon the terms and subject to the conditions set forth therein; and

WHEREAS, in connection with the Credit Agreement, the Obligor and the Parent Borrower have executed and delivered a Ninth Amended and Restated Security Agreement, dated as of the date hereof, in favor of the Agent (together with all amendments and modifications, if any, from time to time thereafter made thereto, the “Security Agreement”);

WHEREAS, pursuant to the Security Agreement, Obligor pledged and granted to the Agent for the benefit of the Agent and the Lenders a continuing security interest in all Intellectual Property, including the Patents; and

WHEREAS, Obligor has duly authorized the execution, delivery and performance of this Agreement;

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and in order to induce the Lenders to make Loans and other financial accommodations to the Parent Borrower pursuant to the Credit Agreement, Obligor agrees, for the benefit of the Agent and the Lenders, as follows:

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided or provided by reference in the Credit Agreement and the Security Agreement.

SECTION 2. Grant of Security Interest. Obligor hereby pledges and grants a continuing security interest in, and a right of setoff against, and effective upon demand made upon the occurrence and during the continuance of an Event of Default assigns, transfers and conveys, the Patents (including, without limitation, those items listed on Schedule A hereto, which includes all of the Obligor’s Patents for which a grant of security interest in patent rights agreement in favor of the Administrative Agent has not previously been filed with the United

States Patent and Trademark Office), to the Agent for the benefit of the Agent and the Lenders to secure payment, performance and observance of the Obligations.


SECTION 3. Purpose. This Agreement has been executed and delivered by Obligor for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The security interest granted hereby has been granted to the Lenders in connection with the Security Agreement and is expressly subject to the terms and conditions thereof. The Security Agreement (and all rights and remedies of the Lenders thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Acknowledgment. Obligor does hereby further acknowledge and affirm that the rights and remedies of the Lenders with respect to the security interest in the Patents granted hereby are more fully set forth in the Credit Agreement and the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.


SECTION 5. Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together constitute one and the same original.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first above written.

CHARLES RIVER LABORATORIES, INC.

By:  \_\_\_\_\_  
Name: David R. Smith  
Title: Corporate Executive VP and CFO

JPMORGAN CHASE BANK, N.A.  
as Administrative Agent for the Lenders

By:   
Name: DAVID HYMAN  
Title: EXECUTIVE DIRECTOR

## SCHEDULE A

### U.S. Patent Registrations

<u>Publication No.</u>	<u>Application No.</u>	<u>Title</u>	<u>Country</u>
10,119,969		Compositions for the Detection of Microbial Contaminants	US
10,473,663		Heat-Treated Limulus Amebocyte Lysates	US
10,473,664		Heat-Treated Limulus Amebocyte Lysates	US
10/465,228		Filtration System and Use Thereof	US
D831223		Filtration System	US
D821604		Blister	US
10,324,036		Cell Capture System and Use Thereof	US
D719666		Cell Detection System with Touchscreen	US
D719666		Cell Detection System	US
D726929		Cup Assembly	US
D829,340		Depressor	US
D821,605		Scanning Device Adapter	US
D829,338		Membrane Holder	US

### U.S. Patent Applications

<u>Application No.</u>	<u>Title</u>	<u>Country</u>
16,133,828	Cho Host Cell Protein Assay	US
63,148,916	Hybrid Amebocyte Lysate and Uses Thereof	US
16,284,495	Cell Capture System and Use Thereof	US
16,675,978	Heat-Treated Limulus Amebocyte Lysate	US
17,178,608	Detection of Infectious Agents from Environmental Air Dust	US
17,193,597	Detection of Infectious Agents from Environmental Air Dust	US
15/577153	Method for Mass Humanization of Rabbit Antibodies	US
16/156,740	Method for Mass Humanization of non-Human Antibodies	US
16/899519	Radically Diverse Human Antibody Library	US